Fate Therapeutics, Inc.
) announced that it has enrolled the first patient in its phase
II study (PUMA −
bilical cord blood transplant in
dults) on Prohema.
Prohema, the lead candidate at Fate Therapeutics, is a
pharmacologically modified hematopoietic stem cell therapeutic
derived from umbilical cord blood. The open-label, randomized,
controlled multi-center study will evaluate the efficacy and
safety of Prohema, when enhanced with a nutrient-rich media
formulation (NRM formulation), in patients undergoing
hematopoietic stem cell (HSC) transplantation for the treatment
of hematologic malignancies.
Fate Therapeutics intends to conduct safety reviews on the
study following the completion of treatment of 6 and 12 patients,
respectively, with Prohema. The company said that it will provide
an update on the study after these reviews are completed. Data
related to the primary efficacy endpoint of the study should be
out in mid-2015.
Meanwhile, Fate Therapeutics is working on strengthening its
pipeline candidates. This year, the company expects to file an
Investigational New Drug application (IND) for a proprietary
Wnt7a protein analog to evaluate its safety and efficacy in
promoting muscle regeneration. Additionally, Fate Therapeutics
intends to conduct studies on Prohema for hematopoietic
reconstitution in both hematologic malignancies and lysosomal
storage disorders (LSDs) in pediatric patients.
Fate Therapeutics carries a Zacks Rank #3 (Hold). Some
better-ranked stocks in the biopharma sector include
Alexion Pharmaceuticals, Inc.
Gilead Sciences Inc.
Biogen Idec Inc.
). While Alexion and Gilead Sciences carry a Zacks Rank #1
(Strong Buy), Biogen holds a Zacks Rank #2 (Buy).
ALEXION PHARMA (ALXN): Free Stock Analysis
BIOGEN IDEC INC (BIIB): Free Stock Analysis
FATE THERAPEUTC (FATE): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
To read this article on Zacks.com click here.